Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations ; volume:40 ; number:5 ; day:5 ; month:4 ; year:2023 ; pages:2147-2185 ; date:5.2023
Advances in therapy ; 40, Heft 5 (5.4.2023), 2147-2185, 5.2023
- Creator
-
Samara, Chrysanthi
Garcia, Alix
Henry, Christopher
Vallotton, Laure
Cariolato, Luca
Desmeules, Jules
Pinçon, Alexis
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02492-3
- URN
-
urn:nbn:de:101:1-2023090410043618521264
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Samara, Chrysanthi
- Garcia, Alix
- Henry, Christopher
- Vallotton, Laure
- Cariolato, Luca
- Desmeules, Jules
- Pinçon, Alexis
- SpringerLink (Online service)
Other Objects (12)
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s Perspective
Surveillance systems evaluation: a systematic review of the existing approaches
Integration of biological molecular data into an existing drug therapy safety workflow used in hospital information systems
Identification of circadian clock modulators from existing drugs
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
Assessing the impacts of vehicle emissions and safety regulations
Cost-benefit analysis (CBA) of health and safety regulations
A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance
Drug safety in Kenya
Antitargets and drug safety
Basics of drug safety
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s Perspective
Surveillance systems evaluation: a systematic review of the existing approaches
Integration of biological molecular data into an existing drug therapy safety workflow used in hospital information systems
Identification of circadian clock modulators from existing drugs
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
Assessing the impacts of vehicle emissions and safety regulations
Cost-benefit analysis (CBA) of health and safety regulations
A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance
Drug safety in Kenya
Antitargets and drug safety
Basics of drug safety
An Evaluation of “Drug Ineffective” Postmarketing Reports in Drug Safety Surveillance
Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor’s Perspective
Surveillance systems evaluation: a systematic review of the existing approaches
Integration of biological molecular data into an existing drug therapy safety workflow used in hospital information systems
Identification of circadian clock modulators from existing drugs
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance
Assessing the impacts of vehicle emissions and safety regulations
Cost-benefit analysis (CBA) of health and safety regulations
A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance
Drug safety in Kenya
Antitargets and drug safety